Literature DB >> 10804153

Norwalk-like virus infection in military forces: epidemic potential, sporadic disease, and the future direction of prevention and control efforts.

M McCarthy1, M K Estes, K C Hyams.   

Abstract

The impact of Norwalk-like virus (NLV) infection on military forces is evaluated in this report. NLVs were a major cause of both outbreaks and sporadic disease among crowded US ground troops in the 1991 war with Iraq. NLVs also have been found to be a cause of acute gastroenteritis in other ground and shipboard deployments. Four large outbreaks of acute gastroenteritis were investigated aboard US Navy aircraft carriers between 1992 and 1997. In these outbreaks, NLVs were identified as the probable cause, and crowding was a major risk factor for transmission. An evaluation of a routine shipboard deployment also suggests that NLVs cause sporadic gastroenteritis. These data indicate that NLV infection is a major cause of acute morbidity in military forces. Because of the limitations of available prevention and control methods, development of a vaccine against these viruses may be the best solution in the military environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804153     DOI: 10.1086/315582

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Evolutionary mechanisms of persistence and diversification of a calicivirus within endemically infected natural host populations.

Authors:  Karen P Coyne; Rosalind M Gaskell; Susan Dawson; Carol J Porter; Alan D Radford
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

2.  Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses.

Authors:  Shannon M Mumphrey; Harish Changotra; Tara N Moore; Ellen R Heimann-Nichols; Christiane E Wobus; Michael J Reilly; Mana Moghadamfalahi; Deepti Shukla; Stephanie M Karst
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Norwalk virus - Off and running.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2003-01

4.  Comparative murine norovirus studies reveal a lack of correlation between intestinal virus titers and enteric pathology.

Authors:  Shannon M Kahan; Guangliang Liu; Mary K Reinhard; Charlie C Hsu; Robert S Livingston; Stephanie M Karst
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

Review 5.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

6.  Methods for ascertaining norovirus disease burdens.

Authors:  David J Allen; John P Harris
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

7.  Type I and type II interferons inhibit the translation of murine norovirus proteins.

Authors:  Harish Changotra; Yali Jia; Tara N Moore; Guangliang Liu; Shannon M Kahan; Stanislav V Sosnovtsev; Stephanie M Karst
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Primary high-dose murine norovirus 1 infection fails to protect from secondary challenge with homologous virus.

Authors:  Guangliang Liu; Shannon M Kahan; Yali Jia; Stephanie M Karst
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

9.  Longitudinal molecular epidemiological analysis of feline calicivirus infection in an animal shelter: a model for investigating calicivirus transmission within high-density, high-turnover populations.

Authors:  Karen P Coyne; David Edwards; Alan D Radford; Peter Cripps; David Jones; James L N Wood; Rosalind M Gaskell; Susan Dawson
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

10.  The feline calicivirus leader of the capsid protein is associated with cytopathic effect.

Authors:  Eugenio J Abente; Stanislav V Sosnovtsev; Carlos Sandoval-Jaime; Gabriel I Parra; Karin Bok; Kim Y Green
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.